Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?

Journal of the American College of Surgeons

Volumn 216, Issue 2, 2013, Pages 239-251

  Greer, Lauren T ^a,b   Rosman, Martin ^b   Mylander, W Charles ^b   Hooke, Jeffrey ^a   Kovatich, Albert ^a,b   Sawyer, Kristen ^c   Buras, Robert R ^b   Shriver, Craig D ^a   Tafra, Lorraine ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ANNE ARUNDEL MEDICAL CENTER   (United States)

^c MDR Global Systems LLC   (United States)

Author keywords

AAMC; Anne Arundel Medical Center; CNB; core needle biopsy; ER; estrogen receptor; FISH; fluorescent in situ hybridization; H E; hematoxylin and eosin; HER2; human epidermal growth factor 2; IHC; immunohistochemical; PR; progesterone receptor; Walter Reed National Military Medical Center; WRNMMC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST CARCINOMA; BREAST TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CORE NEEDLE BIOPSY; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STAINING;

BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872350833     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2012.09.007     Document Type: Conference Paper

References (68)

1. A.M. Gown Current issues in ER and HER2 testing by IHC in breast cancer Mod Pathol 21 2008 S8 S15
2. T. Khoury, S. Sait, and H. Hwang Delay to formalin fixation effect on breast biomarkers Mod Pathol 22 2009 1457 1467
3. J. Qiu, S. Kulkarni, and R. Chandrasekhar Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: A study of three different clones Am J Clin Pathol 134 2010 813 819
4. N.S. Goldstein, M. Ferkowicz, and E. Odish Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma Am J Clin Pathol 120 2003 86 92
5. G.B. Uy, A.V. Laudico, and J.M. Carnate Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients Clin Breast Cancer 10 2010 154 159
6. C.S. Connor, O.W. Tawfik, and A.J. Joyce A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens Am J Surg 184 2002 322 324
7. D.M. Minot, J. Voss, and S. Rademacher Image analysis of HER2 immunohistochemical staining: Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique Am J Clin Pathol 137 2012 270 276
8. X. Chen, Y. Yuan, Z. Gu, and K. Shen Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis Breast Cancer Res Treat 134 2012 957 967
9. K. Tamaki, H. Sasano, and T. Ishida Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients Cancer Sci 101 2010 2074 2079
10. M. Arnedos, A. Nerurkar, and P. Osin Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 2009 1948 1952
11. S.Y. Park, K.S. Kim, and T.G. Lee The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer Am J Surg 197 2009 266 269
12. A. Sutela, R. Vanninen, and M. Sudah Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer Acta Oncol 47 2008 38 46
13. S. Usami, T. Moriya, and M. Amari Reliability of prognostic factors in breast carcinoma determined by core needle biopsy Jpn J Clin Oncol 37 2007 250 255
14. Z. Hodi, J. Chakrabarti, and A.H.S. Lee The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast J Clin Pathol 60 2006 299 302
15. G.B. Mann, V.D. Fahey, F. Feleppa, and M.R. Buchanan Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer J Clin Oncol 23 2005 5148 5154
16. C. Badoual, A. Maruani, and C. Ghorra Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions Breast 14 2005 22 27
17. E. Mueller-Holzner, V. Fink, T. Frede, and C. Marth Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor Breast Cancer Res Treat 69 2001 13 19
18. A.G. Douglas-Jones, N. Collett, J.M. Morgan, and B. Jasani Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma J Clin Pathol 54 2001 951 955
19. W. Hanna, S. Nofech-Mozes, and H.J. Kahn Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event Breast J 13 2007 122 129
20. M. Brunelli, E. Manfrin, and G. Martignoni Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: Evaluation according to ASCO/CAP criteria Am J Clin Pathol 131 2009 678 682
21. W.T. Barry, D.N. Kernagis, and H.K. Dressman Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome J Clin Oncol 28 2010 2198 2206
22. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
23. R.A. Cahill, D. Walsh, R.J. Landers, and R.G. Watson Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy Ann Surg Oncol 13 2006 45 51
24. L. Hernandez, P.M. Wilkerson, and M.B. Lambros Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection J Pathol 227 2012 42 52
25. K. Anderson, C. Lutz, and F.W. van Delft Genetic variegation of clonal architecture and propagating cells in leukaemia Nature 20 469 2011 356 361
26. M. Al-Hajj, M.S. Wicha, and A. Benito-Hernandez Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 2003 3983 3988
27. L.L. Campbell, and K. Polyak Breast tumor heterogeneity Cell Cycle 6 2007 2332 2338
28. P.J. Stephens, D.J. McBride, and M.L. Lin Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 2009 1005 1010
29. G.H. Heppner Tumor heterogeneity Cancer Res 44 1984 2259 2265
30. A. Marusyk, V. Almendro, and K. Polyak Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12 2012 323 334
31. F. Barbieri, R. Wurth, and A. Ratto Isolation of stem-like cells from spontaneous feline mammary carcinomas: Phenotypic characterization and tumorigenic potential Exp Cell Res 318 2012 847 860
32. M. Egeblad, E.S. Nakasone, and Z. Werb Tumors as organs: complex tissues that interface with the entire organism Dev Cell 18 2010 884 901
33. T.D. Tlsty, and L.M. Coussens Tumor stroma and regulation of cancer development Annu Rev Pathol 1 2006 119 150
34. P.B. Gupta, C.M. Fillmore, and G. Jiang Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells Cell 146 2011 633 644
35. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
36. C.G. Marsden, M.J. Wright, R. Pochampally, and B.G. Rowan Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action Methods Mol Biol 590 2009 363 375
37. R.W. Cho, X. Wang, and M. Diehn Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors Stem Cells 26 2008 364 371
38. R.W. Cho, and M.F. Clarke Recent advances in cancer stem cells Curr Opin Genet Dev 18 2008 48 53
39. M. Clarke, J. Dick, and P. Dirks Cancer stem cells: Perspectives on current status and future directions: AACR workshop on cancer stem cells Cancer Res 66 2006 9339 9344
40. N.C. Turner, and J.S. Reis-Filho Genetic heterogeneity and cancer drug resistance Lancet Oncol 13 2012 e178 e185
41. M. Al-Hajj, M.W. Becker, and M. Wicha Therapeutic implications of cancer stem cells Curr Opin Genet Dev 14 2004 43 47
42. G.H. Heppner, D.L. Dexter, and T. DeNucci Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor Cancer Res 38 1978 3758 3763
43. G.H. Heppner, and B.E. Miller Therapeutic implications of tumor heterogeneity Semin Oncol 16 1989 91 105
44. M.E.H. Hammond, D.F. Hayes, and M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med 134 2010 1 25
45. A.C. Wolff, M.E.H. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
46. H.M. Verkooijen Core biopsy after radiological localisation (COBRA) study group Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation Int J Cancer 99 2002 853 859
47. H.M. Verkooijen, P.H. Peeters, and E. Buskens Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis Br J Cancer 82 2000 1017 1021
48. C.M. Perou, T. Surlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
49. M. Cheang, S. Chia, and D. Voduc Ki67 index, HER2 status, and prognosis of patients with Luminal B breast cancer J Natl Cancer Inst 101 2009 736 750
50. A. Goldhirsch, W.C. Wood, and A.S. Coates Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011 Ann Oncol 22 2011 1736 1747
51. F. Marmé, and A. Schneeweiss Personalized therapy in breast cancer Onkologie 35 Suppl 1 2012 28 33
52. M.E. Hammond, D.F. Hayes, and A.C. Wolff Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer J Clin Oncol 29 2011 e458
53. F. Petrelli, and S. Barni Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better Med Oncol 29 2012 503 510
54. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
55. H. Joensuu, P.L. Kelloukumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820
56. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
57. L. Gianni, U. Dafni, and R.D. Gelber Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 2011 236 244
58. D.J. Williams, C. Cohen, and M. Darrow Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer Appl Immunohistochem Mol Morphol 19 2011 431 436
59. E. de Azambuja, F. Cardoso, and G. de Castro Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 2007 1504 1513
60. R. Stuart-Harris, C. Caldas, S.E. Pinder, and P. Pharoah Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients Breast 17 2008 323 334
61. M. Dowsett, T.O. Nielsen, and R. A'hern Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group J Natl Cancer Inst 2011 1031656 1031664
62. J. Cuzick, M. Dowsett, and S. Pineda Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer J Clin Oncol 29 2011 4273 4278
63. L. Zabaglo, J. Salter, and H. Anderson Comparative validation of the SP6 antibody to Ki67 in breast cancer J Clin Pathol 63 2010 800 804
64. M. Werner, A. Chott, A. Fabiano, and H. Battifora Effect of formalin tissue fixation and processing on immunohistochemistry Am J Surg Pathol 24 2000 1016 1019
65. P.A. Kaplan, S.R. Frazier, and T.S. Loy ID5 and 6F11: An immunhistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma Am J Clin Pathol 123 2005 276 280
66. J. Vassallo, G.A. Pinto, and M. Alvarenga Comparison of immunoexpression of 2 antibodies for estrogen recepts (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods Appl Immunohistochem Mol Morphol 12 2004 177 182
67. B.H. Hall, M. Ianosi-Irimie, and P. Javidian Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls BMC Med Imaging 8 2008 11
68. A. Nassar, C. Cohen, and S.S. Agersborg Trainable immunohistochemical HER2/neu image analysis Arch Pathol Lab Med 135 2011 896 902